Abstract
In this study, we planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD). The patients were grouped according to the characteristics and the sites of metastases. Group I included 928 patients without metastasis. Group II, the OMBD group, included 68 patients. Group III, the widespread metastasis group, comprised 185 patients with multiple bone metastases and/or solid organ metastases. The mean overall survival of the groups was 16.7 ± 0.3 years in group 1, and 7.8 ± 0.8 and 5.9 ± 0.4 years in groups 2 and 3, respectively (p < 0.001 for the comparison of all three groups together; p < 0.001 for group 1 vs. 2 and 3) and (p = 0.037 for group 2 vs. group 3). In the subgroup survival analysis of patients in group 2 (OMBD), the mean and median survival was 5.5 ± 0.8 and 4.0 ± 0.8 years vs. 9.2 ± 0.98 and 9.0 ± 1.05 years in patients with more than one bone metastasis and single bone metastasis, respectively (p = 0.019). OMBD seems to be a different disease than breast cancer with isolated bone metastases. The high risk of developing OMBD, especially following locoregional recurrence, increases the importance of locoregional therapy in large T and N stage tumors.
Highlights
In this study, we planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD)
We evaluated the demographic features of patients, histopathologic features with intrinsic subtypes of tumors and treatment-related factors on “survival outcomes” among a nonmetastatic group, an OMBD group, and a widespread metastatic group that included patients with solid organ metastases with or without bone metastasis (Fig. 1)
Breast-conserving surgery (BCS) was performed more frequently in patients in group 1 (44.5%) than in groups 2 (13.2%) and 3 (11.9%) (p < 0.001)
Summary
We planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD). The survival outcomes of patients with stage IV breast cancer vary according to metastatic site and those with bone metastasis have the best survival[6]. In this context, oligometastatic breast cancer generally refers to a special group of patients with fewer than five metastatic deposits in a single organ and is considering potentially curable stage IV d isease[7]. We evaluated the demographic features of patients, histopathologic features with intrinsic subtypes of tumors and treatment-related factors on “survival outcomes” among a nonmetastatic group (group I), an OMBD group (group II), and a widespread metastatic group that included patients with solid organ metastases with or without bone metastasis (group III) (Fig. 1). A sub-group analysis was conducted to compare two strata of the OMBD group (group II), comparing patients with solitary bone metastasis (group IIa) and patients with OMBD (group IIb)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
